Newspaper Advertisement pertaining to Unaudited Financial results of the company for the quarter ended on 30.06.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Terce Laboratories has published its unaudited standalone financial results for the quarter ended June 30, 2025, which were approved by the Board on August 11, 2025 and reviewed by statutory auditors. Revenue from operations rose to Rs. 1,188.88 lakhs from Rs. 1,085.36 lakhs in the same quarter last year, a year-on-year growth of about 9.5%. However, the company reported a wider net loss of Rs. 7.76 lakhs after tax in Q1 FY26, compared to a loss of Rs. 4.35 lakhs in Q1 FY25. Earnings per share stood at Rs. (0.10) for the quarter, and reserves remain negative at Rs. (7.76) lakhs, indicating accumulated losses continue to exceed equity capital. For reference, the full FY25 (audited) had revenue of Rs. 5,019.52 lakhs and a net loss of Rs. 97.87 lakhs.
Modest revenue growth is a small positive, but the widening quarterly loss and negative reserves signal continued financial stress for shareholders. The stock is likely to see a muted to negative reaction, with no earnings support at current levels.